Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.

Elisabetta BuscariniLuisa Maria BotellaUrban GeisthoffAnette D KjeldsenHans Jurgen MagerFabio PagellaPatrizia SuppressaRoberto ZarrabeitiaSophie Dupuis-GirodClaire L Shovlinnull null

Published in: Orphanet journal of rare diseases (2019)

With potential increase in use of Bevacizumab and Thalidomide in HHT patients, data presented support appropriate weighing of the toxicities which can arise in HHT settings and the practice recommendations for their prevention and management.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
peritoneal dialysis
machine learning
patient reported outcomes
big data
risk assessment
human health
deep learning